CSI Medical Research
CSI Medical Research is a Singapore-based contract research organization (CRO) providing biostatistics, data management, project management, medical monitoring, and pharmacovigilance services for pharmaceutical, biotech, medical device, and academic clients conducting clinical trials across Southeast Asia, Australia, and New Zealand. Acquired by ClinChoice in January 2024.
- Company typePrivate
- Founded2017
- HeadquartersBedok, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingServices
What CSI Medical Research does
CSI Medical Research (CSI Medical Research Pte Ltd) is a Singapore-based contract research organization (CRO) incorporated in 2017 that delivers clinical research services across Asia-Pacific, with operating entities in Singapore (HQ), Malaysia (since 2020), Australia (since 2022), and Thailand. The company serves pharmaceutical, biotechnology, medical device companies, and academic institutions conducting trials in Southeast Asia and Oceania, executing work across all clinical phases with a documented phase mix of 35% Phase 1, 22% Phase 2, 8% Phase 3, and 35% Phase 4 across approximately 100 awarded projects and roughly 50 active regional studies.
The company's service portfolio spans the full clinical development lifecycle, including Pre-Study Consultation, Site Feasibility, Regulatory & Start-Up, Clinical Operations (ICH-GCP compliant), Project Management, Clinical Biostatistics, Site Management, Data Management, Quality Assurance, Pharmacovigilance (powered by the Oracle Argus safety database), Medical Monitoring, Medical Writing, and Post-Marketing & New Drug Application support. Data management integrates three electronic data capture (EDC) platforms — Medidata, Viedoc, and Taimei Technology's eCollect — alongside MedDRA coding for standardized medical terminology. The technology stack relies on licensed third-party enterprise tools rather than proprietary platforms.
CSI generates revenue through professional service fees on multi-year, project-based contracts priced via a quote-based model (no public pricing). Go-to-market is direct enterprise field sales supported by regional managers across SEA, Australia, and New Zealand, with lead capture through a website "Request a Quote" form and pipeline development through industry conference participation (BIO Asia-Taiwan, ARCS Conference, DIA China, CMAC, CRM Trial Connect). On January 12, 2024, the company was acquired by ClinChoice, a global CRO with over 4,000 professionals operating in more than 30 countries, which materially expanded CSI's distribution footprint and full-service capabilities while the founder/CEO Nelson Wong retained leadership.
CSI Medical Research firmographics
Firmographics- Name
- CSI Medical Research
- Legal name
- CSI Medical Research Pte Ltd
- Website
- https://csimedicalresearch.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- CSI Medical Research is a Singapore-based contract research organization (CRO) providing biostatistics, data management, project management, medical monitoring, and pharmacovigilance services for pharmaceutical, biotech, medical device, and academic clients conducting clinical trials across Southeast Asia, Australia, and New Zealand. Acquired by ClinChoice in January 2024.
- Ownership category
- akta.pro rank
CSI Medical Research industry classification
Industry- Product category
- Contract Research Organization Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171), Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical CROs (Phase I–IV) (HLAGAAAA)
- akta.pro secondary industries
- Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Clinical Trial Site Operations & Study Coordination (HLAGACAE)
Keywords
Where CSI Medical Research is headquartered
LocationHeadquarters
- HQ city
- Bedok
- HQ country
- Singapore
- HQ region
- Asia
Offices4 records
Markets served
CSI Medical Research business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Research Services: CSI Medical Research generates revenue by providing comprehensive contract research organization (CRO) services to pharmaceutical, biotech, medical device companies, and academic institutions. Services are delivered across clinical trial phases and include project-based professional service fees. The company was acquired by ClinChoice on January 12, 2024, expanding ClinChoice's global footprint in over 30 countries.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom enterprise service packages based on study requirements |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
CSI Medical Research product offering
Product offeringCore offering
CSI Medical Research is a contract research organization (CRO) that delivers end-to-end clinical research services for pharmaceutical, biotechnology, medical device, nutraceutical, and academic sponsors across Asia-Pacific. Its service portfolio spans pre-study consultation, regulatory and start-up, clinical operations, project management, medical monitoring, site feasibility, biostatistics, clinical data management (using EDC systems such as Medidata, Viedoc, and Taimei), pharmacovigilance (via the Oracle Argus AI safety database), quality assurance, medical writing, and post-marketing and NDA support across Phase 1 first-in-human through Phase 4 and real-world studies.
Product overview
CSI Medical Research is a contract research organization (CRO) offering a unified portfolio of integrated clinical research services spanning the entire drug development lifecycle. The service suite includes Pre-Study Consultation, Clinical Operations (monitoring, site management), Quality Assurance, Medical Writing, Project Management, Medical Monitoring, Site Feasibility, Biostatistics, Pharmacovigilance (powered by Oracle Argus AI platform), Regulatory & Start-Up, Data Management (supporting Medidata, Viedoc, and Taimei eCollect EDC systems), and Post Marketing & New Drug Application services. The company conducts Phase 1 first-in-human trials, proof-of-concept studies, and Phase 2-4 trials across pharmaceuticals, medical devices, investigator-initiated trials, nutraceuticals, and real-world studies in the Asia-Pacific region.
Differentiator
Problem solved
Functional benefit
Products and services
- Pre-Study Consultation
- Clinical Operations Comprehensive monitoring and site management services including site contract and budget negotiation, regulatory and ethics submission, site selection and initiation, site/remote monitoring, and study close-out, compliant with ICH-GCP and applicable regulatory requirements.
- Project Management Cross-functional project coordination providing a single point of contact for project delivery from start to end, covering all therapeutic areas and clinical development phases.
- Site Feasibility Feasibility assessment for conducting clinical trials in specific geographical regions and clinical sites, including site identification, patient recruitment estimation, regulatory support, and budget/timeline management.
- Regulatory & Start-Up Regulatory submission and clinical trial start-up services including regulatory dossier preparation, clinical input for agency queries, strategic regulatory planning, and regulatory consulting across Asia-Pacific jurisdictions.
- Medical Monitoring Safety oversight and medical expertise services including protocol design consultation, medical monitoring plan development, adverse event evaluation, and medical consultation for study reports.
- Biostatistics Statistical analysis services for clinical research including sample size determination, statistical analysis planning, data analysis, study design guidance, and protocol development support.
- Data Management Clinical trial data management including EDC system setup (Medidata, Viedoc, Taimei eCollect), eCRF design, database build and testing, data capture, discrepancy management, MedDRA coding, SAE reconciliation, quality control, database lock, and archival.
- Pharmacovigilance Patient safety optimization services using the Oracle Argus AI-powered safety database for SAE processing, narrative writing, medical review, safety reporting, training, aggregate report writing (PSUR/DSUR), and database reconciliation.
- Medical Writing Documentation services for drug development including clinical trial protocols, investigator brochures, clinical study reports, journal article publication support, and Common Technical Document (CTD) preparation.
- Quality Assurance Quality assurance services ensuring products or services meet established quality standards, including process review, quality issue identification, inspections, audits, and compliance testing for clinical trial activities.
- Post Marketing & New Drug Application Support services for post-marketing activities and new drug application processes for approved products, including post-marketing surveillance and regulatory submissions.
Quantifiable outcome
- Nearly 50 clinical studies currently active in Southeast Asia, Australia, and New Zealand
- +2 more outcomes
Companies that use CSI Medical Research
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles4 records
CSI Medical Research technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability2 records
Feature4 records
CSI Medical Research partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- ClinChoicecoreOn January 12, 2024, CSI Medical Research was acquired by ClinChoice, a leading global CRO with over 4,000 professionals worldwide operating in over 30 countries across Asia, Europe, and North America. The acquisition expands ClinChoice's global footprint and full-service capabilities into Southeast Asia, with CSI Medical Research becoming part of the ClinChoice group. CSI's operations continue under the parent company, strengthening ClinChoice's Asia-Pacific presence.
- Local CRO Partners in Southeast AsiaminorCSI Medical Research has established partnerships with local CROs in the Southeast Asian region to provide governance, oversight, and quality delivery for customers. This partnership model enables CSI to offer multi-country study execution across the region.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
CSI Medical Research competitors and assessment
Company assessmentBroad incumbents
- Parexel International: Global CRO offering full-service clinical development, including APAC operations. Parexel competes with CSI for biotech and pharma sponsors seeking multi-region study execution and is a key alternative for large sponsors.
- Syneos Health: Global biopharmaceutical solutions organization with clinical and commercial services. Syneos is a broad incumbent competitor for enterprise sponsors comparing full-service CROs against regional specialists like CSI.
- IQVIA: Global CRO and life sciences services leader. IQVIA competes with CSI on enterprise pharma studies and increasingly expands its APAC footprint, putting pressure on regional specialists for late-stage and complex trials.
- Medpace Holdings: Mid-to-large global CRO focused on small and mid-sized biopharma. Medpace represents the alternative enterprise CRO for sponsors weighing CSI's regional offering versus a global full-service model with structured study execution.
- ICON plc: Global CRO with extensive Asia-Pacific operations including Australia and Singapore. ICON is a broad incumbent competitor for any sponsor evaluating CSI versus a full-service global alternative.
Regional players
- Wuxi AppTec: China-headquartered CRO/CDMO with growing APAC clinical operations and laboratory services. Wuxi is a regional peer competing for multi-country trials and adjacent services for biotech sponsors expanding into SEA.
- Tigermed (Hangzhou Tigermed): China's largest CRO, providing clinical trial services across Asia with growing presence in Australia and Southeast Asia. Tigermed is a regional peer competing for multi-country APAC trials and has historically been referenced as a comparable regional CRO play.
Direct peers
- ClinChoice: CSI Medical Research's parent company since January 2024. ClinChoice is a global CRO with 4,000+ professionals across 30+ countries, offering full-service clinical development. As CSI's acquirer, ClinChoice is the closest structural and operational peer, now operating CSI's SEA business as part of a larger integrated CRO delivery model.
- Pharmaron: China-based integrated CRO/CDMO with growing APAC clinical operations and laboratory services. Comparable to CSI on early-phase clinical execution and the cross-border China-into-SEA sponsor flow.
- Novotech: Asia-Pacific-focused CRO headquartered in Australia with deep SEA presence. Novotech competes directly with CSI in Phase 1–3 clinical trials for biotech and pharma sponsors across ANZ and Southeast Asia, and is now part of the same global CRO consolidation trend.
Market position
Strengths5 records
Weaknesses3 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
CSI Medical Research social profiles
Digital presenceCSI Medical Research compliance and trust
Trust signalCompliance1 record
CSI Medical Research financial estimates
Financial estimateRevenue estimate
Valuation estimate
CSI Medical Research leadership team
Management profileNumber of profiles
Profiles8 records
CSI Medical Research funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CSI Medical Research M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CSI Medical Research
What does CSI Medical Research do?
CSI Medical Research is a contract research organization (CRO) that delivers end-to-end clinical research services for pharmaceutical, biotechnology, medical device, nutraceutical, and academic sponsors across Asia-Pacific. Its service portfolio spans pre-study consultation, regulatory and start-up, clinical operations, project management, medical monitoring, site feasibility, biostatistics, clinical data management (using EDC systems such as Medidata, Viedoc, and Taimei), pharmacovigilance (via the Oracle Argus AI safety database), quality assurance, medical writing, and post-marketing and NDA support across Phase 1 first-in-human through Phase 4 and real-world studies.
Is CSI Medical Research a public or private company?
CSI Medical Research is a private company. It is classified as corporate owned and is currently acquired.
When was CSI Medical Research founded?
CSI Medical Research was founded in 2017. It employs 11 to 50 people.
Where is CSI Medical Research based?
CSI Medical Research is headquartered in Bedok, Singapore, in the Asia region.
How does CSI Medical Research make money?
One revenue line is on record: clinical Research Services.
Who are CSI Medical Research's main competitors?
Broad incumbents on record are Parexel International, Syneos Health, IQVIA, Medpace Holdings and ICON plc. Regional players are Wuxi AppTec and Tigermed (Hangzhou Tigermed). Direct peers are ClinChoice, Pharmaron and Novotech.
Does CSI Medical Research have an API?
No public API is recorded for CSI Medical Research.
What industry is CSI Medical Research in?
CSI Medical Research's product category is Contract Research Organization Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAF, Clinical Data Management, Biostatistics & Statistical Programming CROs. Its NAICS code is 5417 and its SIC code is 8731.